ILLUMINA, INC. (ILMN) Form 8-K — Oct 29, 2026
Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% year over year, with GAAP diluted EPS of $1.43 and non-GAAP EPS excluding tariff refunds of $1.44, beating its guidance on healthy clinical demand and strong NovaSeq X placements. CEO Jacob Thaysen said results exceeded guidance and the company raised full-year fiscal 2026 guidance, now expecting revenue of $4.64-$4.66 billion and non-GAAP diluted EPS of $5.40-$5.45. Free cash flow was $378 million versus $253 million a year ago, and the company held $1.34 billion in cash and short-term investments.
Key figures
- Eps
- 1.43
- Revenue
- 1129000000
- Guidance
- FY2026 revenue of $4.64-$4.66B (raised from $4.60-$4.64B); non-GAAP diluted EPS of $5.40-$5.45 (raised from $5.30-$5.40); non-GAAP operating margin of 23.6%
- Net Income
- 220000000
- Revenue Yoy
- 4.2%
- Cash Position
- 1340000000
- Free cash flow
- 378000000
- Operating cash flow
- 419000000
- Gaap operating margin
- 27.0%
- Organic revenue growth
- 4.8%
- Row organic revenue growth
- 4.7%
- Non gaap eps ex tariff refunds
- 1.44
- Tariff refund revenue reduction
- 37000000
- Tariff refund benefit cost of revenue
- 79000000
- Non gaap operating margin ex tariff refunds
- 25.0%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.